Press Releases Kancera AB

Equities

KAN

SE0015658570

Market Closed - Nasdaq Stockholm Other stock markets 11:13:40 2024-05-16 am EDT			5-day change	1st Jan Change
1.68 ^SEK	+0.36%		+14.29%	-63.04%

May. 08	Kancera AB Announces Executive Changes	CI
May. 03	Kancera AB Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kancera provides operational update regarding the KANDOVA study and reports increased patient recruitment	May. 16	AQ
Kancera appoints new Chief Scientific Officer and extends management team	May. 08	AQ
Kancera meets the primary objectives of the KAND145 clinical phase I study	May. 03	AQ
Kancera announces the outcome of the company's rights issue	Mar. 20	AQ
Kancera publishes prospectus in connection with the company’s rights issue	Mar. 01	AQ
Kancera resolves on a rights issue of approximately SEK 121.9 million	Feb. 23	AQ
Interim Report Fourth Quarter 2023, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851	Feb. 23	AQ
Kancera signs license agreement and obtains global commercial rights to the results from the FRACTAL study	Feb. 23	AQ
Kancera presents the statistical analysis of top line data from the FRACTAL study	Feb. 06	AQ
Kancera reports positive top line results from the FRACTAL study	Dec. 20	AQ
Kancera provides operational update in connection with release of financial interim report for third quarter 2023	Nov. 17	AQ
Interim Report Third Quarter July 1 – September 30, 2023 Kancera AB (publ.), org.no. 556806-8851	Nov. 17	AQ
Kancera reports that the phase I study of KAND145 has received regulatory approval	23-10-23	AQ
Kancera announces that the FRACTAL top line results are expected to be presented by the end of December 2023	23-10-13	AQ
Kancera appoints new Chief Medical Officer	23-09-01	AQ
Kancera provides operational update in connection with release of financial interim report for second quarter	23-08-18	AQ
Interim Report Second Quarter April 1 – June 30 2023 Kancera AB (publ.), org.no. 556806-8851	23-08-18	AQ
Newly published research publication confirms the potential for Kancera’s fractalkine blocker KAND567 in cardiovascular disease	23-07-24	AQ
Kancera reports dosing of first patient in the KANDOVA study	23-06-19	AQ
Kancera appoints Peter Selin as new Chief Executive Officer	23-05-26	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Kancera AB

Equities

KAN

SE0015658570

Press Releases

Filters